RANI THERAPEUTICS HOLDINGS-A (RANI) Stock Overview
USA - NASDAQ:RANI - US7530181004 - Common Stock
RANI Key Statistics, Chart & Performance
The current stock price of RANI is 1.82 USD. In the past month the price increased by 279.17%. In the past year, price decreased by -22.22%.
RANI Latest News, Press Relases and Analysis
RANI Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 51.11 | 781.26B | ||
| JNJ | JOHNSON & JOHNSON | 18.34 | 458.55B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 18.76 | 258.24B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 14.73 | 252.36B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 13.65 | 235.32B | ||
| MRK | MERCK & CO. INC. | 11.36 | 218.53B | ||
| PFE | PFIZER INC | 7.3 | 140.77B | ||
| SNY | SANOFI-ADR | 14.34 | 125.85B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 6.51 | 89.21B | ||
| GSK | GSK PLC-SPON ADR | 9.67 | 86.97B | ||
| ZTS | ZOETIS INC | 23.46 | 64.68B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 50.04 | 44.25B |
Related stock screener links
About RANI
Company Profile
Rani Therapeutics Holdings, Inc. engages in the operation of a clinical stage bio-therapeutics company. The company is headquartered in San Jose, California and currently employs 105 full-time employees. The company went IPO on 2021-07-30. The firm has developed the RaniPill capsule, which is a proprietary and patented platform technology, intended to replace subcutaneous injection or intravenous infusion of biologics and drugs with oral dosing. The RaniPill capsule is designed to deliver a variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. The company has two configurations of the platform: the RaniPill GO and the RaniPill HC. The RaniPill GO is designed to deliver up to a 3 mg dose of drug in microtablet form with high bioavailability. The company is also developing a high-capacity version of the RaniPill capsule known as the RaniPill HC. Its product candidate pipeline includes obesity programs (RT-114 and RT-116), immunology programs (RT-105 and RT-111) and endocrinology programs (RT-102 and RT-110).
Company Info
RANI THERAPEUTICS HOLDINGS-A
2051 Ringwood Avenue
San Jose CALIFORNIA US
CEO: Talat Imran
Employees: 105
Phone: 14084573700
RANI THERAPEUTICS HOLDINGS-A / RANI FAQ
Can you describe the business of RANI THERAPEUTICS HOLDINGS-A?
Rani Therapeutics Holdings, Inc. engages in the operation of a clinical stage bio-therapeutics company. The company is headquartered in San Jose, California and currently employs 105 full-time employees. The company went IPO on 2021-07-30. The firm has developed the RaniPill capsule, which is a proprietary and patented platform technology, intended to replace subcutaneous injection or intravenous infusion of biologics and drugs with oral dosing. The RaniPill capsule is designed to deliver a variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. The company has two configurations of the platform: the RaniPill GO and the RaniPill HC. The RaniPill GO is designed to deliver up to a 3 mg dose of drug in microtablet form with high bioavailability. The company is also developing a high-capacity version of the RaniPill capsule known as the RaniPill HC. Its product candidate pipeline includes obesity programs (RT-114 and RT-116), immunology programs (RT-105 and RT-111) and endocrinology programs (RT-102 and RT-110).
What is the current price of RANI stock?
The current stock price of RANI is 1.82 USD. The price decreased by -12.92% in the last trading session.
Does RANI stock pay dividends?
RANI does not pay a dividend.
What is the ChartMill technical and fundamental rating of RANI stock?
RANI has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
What is the employee count for RANI stock?
RANI THERAPEUTICS HOLDINGS-A (RANI) currently has 105 employees.
What is the ownership structure of RANI THERAPEUTICS HOLDINGS-A (RANI)?
You can find the ownership structure of RANI THERAPEUTICS HOLDINGS-A (RANI) on the Ownership tab.
RANI Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to RANI. When comparing the yearly performance of all stocks, RANI is one of the better performing stocks in the market, outperforming 96.49% of all stocks.
RANI Financial Highlights
Over the last trailing twelve months RANI reported a non-GAAP Earnings per Share(EPS) of -0.91. The EPS increased by 22.88% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -175.68% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
RANI Forecast & Estimates
9 analysts have analysed RANI and the average price target is 8.93 USD. This implies a price increase of 390.38% is expected in the next year compared to the current price of 1.82.